Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
Tracking the 2022 ASCO Live Event | Where’s the Amazing Report?!
View details
→
Nivolumab has achieved a major breakthrough in the treatment of esophageal cancer; interim analysis from the Phase III study was selected for poster discussion at the 2022 ASCO meeting.
The groundbreaking NOTABLE study makes a major impact, paving the way for a new era in pancreatic cancer diagnosis and treatment.
Biotech Pharma Pharmaceuticals announced clinical study data on nimotuzumab for the treatment of pancreatic cancer—results that are truly encouraging.
Studies show that nimotuzumab demonstrates significant efficacy in treating pancreatic cancer, marking a major breakthrough for patients with advanced-stage disease.
[3210] [2022 ASCO] Biotech Pharma's Nimotuzumab Clinical Study Achieves Major Breakthrough, Ushering in a New Era for Pancreatic Cancer Treatment